- News Library
- Servier Medical Art
- Partnering & Licensing
Press release: Servier/SAIDAL10/04/2014
Mr Frédéric SESINI, Servier’s International Operations Managing Director and Mr DERKAOUI, CEO of the SAIDAL Group.
Algiers, Tuesday 8 April 2014: Servier and the Algerian company SAIDAL today signed an agreement concerning production for the local market of drugs prescribed in the treatment of cardiovascular diseases.
This agreement was signed at the Ministry of Industry in the presence of Mr BENYOUNES, the Algerian Minister of Industrial Development and Investment Promotion, and Mr DERKAOUI, CEO of the SAIDAL Group.
Mr Frédéric SESINI, Servier’s International Operations Managing Director, on the occasion of the signature, declared: “This agreement represents a crucial step in the operations of the SERVIER Group in Algeria. For the first time, the SERVIER Group has the opportunity to engage in significant production of several of its key drugs on the Algerian territory.”
Founded in 1954, Servier is an independent French pharmaceutical research company. Its development is based on the continuous pursuit of innovation in the therapeutic areas of cardiovascular, metabolic, neurologic, psychiatric, bone and joint diseases, as well as cancer. In 2013, the company recorded a turnover of 4.2 billion euros.
- 91% of Servier drugs are consumed outside of France.
- 27% of turnover from Servier drugs were reinvested in Research and Development in 2013.
- With a strong international presence in 140 countries, Servier employs more than 21 000 people worldwide.
- The Servier Group contributed 35% to the 2013 French trade surplus in the pharmaceuticals sector.